1. Signaling Pathways
  2. GPCR/G Protein
  3. RGS Protein
  4. RGS Protein Inhibitor

RGS Protein Inhibitor

RGS Protein Inhibitors (6):

Cat. No. Product Name Effect Purity
  • HY-13509
    CCG-50014
    Inhibitor 99.42%
    CCG-50014 is the most potent against the regulator of G-protein signaling protein type 4 (RGS4) (IC50 =30 nM) and is >20-fold selective for RGS4 over other RGS proteins. CCG-50014 binds covalently to the RGS, forming an adduct on two cysteine residues located in an allosteric regulatory site. CCG50014, reduces nociceptive responses and enhances opioid-mediated analgesic effects in the mouse formalin test.
  • HY-U00431
    CCG 203769
    Inhibitor 99.76%
    CCG 203769 is a selective G protein signaling (RGS4) inhibitor, which blocks the RGS4-Gαo protein-protein interaction in vitro with an IC50 of 17 nM.
  • HY-70074
    CCG-63802
    Inhibitor 98.83%
    CCG-63802 is a selective, reversible and allosteric RGS4 inhibitor. CCG-63802 specifically binds to RGS4 and blocks the RGS4-Gαo interaction, with an IC50 value of 1.9 μM.
  • HY-70075
    CCG-63808
    Inhibitor ≥98.0%
    CCG-63808 is a reversible inhibitor of regulator of G-protein signaling (RGS) proteins.
  • HY-122251
    CCG-4986
    Inhibitor
    CCG-4986 is an RGS protein inhibitor. CCG-4986 inhibits protein activity by covalently modifying the Cys-132 site of RGS4. CCG-4986 can be used to study diseases related to dysregulated G protein-coupled receptor (GPCR) signaling, such as Parkinson's disease and opioid addiction.
  • HY-110054
    CCG-2046
    Inhibitor
    CCG-2046 is a RGS4 inhibitor with an IC50 of 4.3 μM against RGS4-Gαo interaction signal.